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Abstract
Purpose The criteria to screen for Gestational Diabetes Mellitus are not internationally consensual. In opposition to the
universal screening performed in Portugal, certain countries advocate a risk-factor-based screening. We aim to compare
obstetric and neonatal outcomes in pregnant women with and without risk factors treated for Gestational Diabetes Mellitus.
Methods Retrospective and multicentric study of 12,006 pregnant women diagnosed with Gestational Diabetes Mellitus
between 2011 and 2015, in Portugal. Gestational Diabetes Mellitus was diagnosed according to the International Association
of the Diabetes and Pregnancy Study Groups criteria. Risk factors: body mass index > 30kg/m2, history of Gestational
Diabetes Mellitus, history of macrossomic newborn (birth weight > 4000 g) or first-degree relatives with Type 2 Diabetes
Mellitus. Exclusion criteria: lack of data concerning risk factors (n= 1563).
Results At least one risk factor was found in 68.2% (n= 7123) pregnant women. Pregnant women with risk factors were
more frequently medicated with insulin (p < 0.001), caesarean section was more commonly performed (p < 0.001), their
newborns were more frequently large-for-gestational-age (p < 0.001) and neonatal morbidity was higher (p= 0.040) in
comparison to pregnant women without risk factors. The Diabetes Mellitus reclassification test showed an increased
frequency of intermediate hyperglycaemia and Diabetes Mellitus in women with risk factors (p < 0.001).
Conclusion Almost one-third of pregnant women would have remained undiagnosed if risk-based-factor screening were
implemented in Portugal. Women without risk factors presented fewer obstetric and neonatal complications. However, more
than one third required insulin therapy.
Keywords Diabetes gestational ● Risk factors ● Diagnosis ● Mass screening
Introduction
Gestational Diabetes Mellitus (GDM) is defined as a sub-
type of abnormal glucose tolerance resulting in hypergly-
caemia of variable severity with onset during pregnancy. It
is associated with an increased risk of adverse maternal,
foetal and neonatal outcomes [1]. In Portugal, in 2015, the
prevalence of GDM was 7.2% [2]. The criteria to screen for
GDM are not internationally consensual [3]. The World
Health Organization (WHO) recommended that local
authorities ought to decide on the screening coverage
depending on local resources and priorities [4]. In Portugal,
screening for GDM is offered to all pregnant women [5].
However, in certain countries, like the United Kingdom, the
screening is risk-factor-based [6]. Universal screening
allows higher GDM detection rates, but more women are
subjected to inconvenient testing, there is additional preg-
nancy medical intervention with increased health care costs
and further maternal anxiety [7]. Besides, it has been sug-
gested that the additional cases detected exhibit a milder to
moderate hyperglycaemia [8] and might have less clinical
significance [9]. Currently, the scientific evidence available
is insufficient to favour a screening method [7]. The
National Institute for Health and Care Excellence (NICE)
clinical practice recommendations consider that the cost-
effectiveness ratios do not support universal screening [6].
The diagnostic criteria for GDM of the International
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Association of the Diabetes and Pregnancy Study Group
(IADPSG) [10] is based on the Hyperglycaemia and
Adverse Pregnancy Outcome study [11]. These criteria
were implemented in Portugal in 2011, lowering the
threshold for GDM and subsequently more women have
been diagnosed with GDM [2]. Furthermore, more women
with GDM are expected due to the obesity epidemic and
increased maternal age [12], straining the Portuguese
National Health System.
We hypothesised that pregnant women with risk factors
(RF) presented worse obstetric and neonatal outcomes
compared to women without RF. Thus, we aim to compare
obstetric and neonatal outcomes between these two groups,
and therefore reflect about risk-factor-based vs. universal
screening for GDM.
Materials and methods
Data sources and collection
This is a retrospective cohort study of 12,006 pregnant
women based on data from the Portuguese National Reg-
istry of Gestational Diabetes. The register is organized by
the Portuguese Diabetes and Pregnancy Study Group of the
Portuguese Society of Diabetology. The data is collected
from 28 hospitals from all regions of Portugal and only
includes pregnant women with GDM. The register is
voluntary. We included pregnant women with GDM that
gave birth from 2011 to 2015. The medical team obtained
information about the pregnant women with GDM since the
first consultation until the Diabetes Mellitus (DM) reclas-
sification test. The data was anonymised and none of the
authors had access to patient identification. We excluded
1563 women due to a lack of data regarding RF. The final
sample was constituted by 10,443 pregnant women.
Definitions
The diagnosis of GDM, according to IADPSG, is estab-
lished by fasting plasma glucose (FPG) at the first pre-natal
visit, between the 11th and 13th week plus 6 days gesta-
tional age, or by a 2 h 75-g oral glucose tolerance test
(OGTT) performed between 24 and 28 weeks of gestation
[10]. The diagnostic criteria for GDM are FPG between 92
and 125 mg/dL, or plasma glucose 92–125 mg/dL, superior
to 180 mg/dL or 153–199 mg/dL at 0, 60, or 120 min,
respectively, with the 2 h 75-g OGTT [5]. All pregnant
women diagnosed with GDM were referred to a specialized
diabetes care team including a diabetologist, an obstetrician,
a dietician, and a nurse. They were instructed to evaluate
capillary glycaemia four times a day, at fasting and 1-h after
the beginning of the three main meals. The pregnant women
with GDM were seen by the diabetologist every 1–4 weeks.
A personalised diet was recommended to all women. The
glycaemic targets defined were less than 90 mg/dL at fasting
and less than 120 mg/dL 1-h after meals. Pharmaceutical
intervention with metformin or insulin was initiated if these
glycaemic targets were not accomplished with nutritional
therapy and physical activity after one or two weeks.
Metabolic control and further therapeutic adjustments were
assessed by glycaemic patterns, ultra-sound foetal devel-
opment, and amniotic fluid changes. The newborns were
classified as large-for-gestational-age (LGA) and small-for-
gestational-age (SGA) if their weight for gestational age
was superior to 90th percentile (P90) or inferior to 10th
percentile (P10) respectively, according to Fenton Growth
charts. Neonatal morbidity comprised neonatal hypogly-
caemia, neonatal hyperbilirubinemia, respiratory distress
syndrome, congenital anomalies, and intensive care unit
hospitalisation. We considered RF in light of NICE guide-
lines recommendations: body mass index (BMI) > 30 kg/m2
(obesity), history of GDM, history of macrossomic newborn
(birth weight > 4000 g) or first-degree relatives with Type 2
Diabetes Mellitus (T2DM). The criteria about ethnic family
origin was not considered. The type of delivery was divided
into eutocic, vaginal instrumented delivery (forceps and
ventouse) and caesarean. Six to eight weeks after delivery,
all women were invited to undergo the DM reclassification
test with 2 h 75-g OGTT. According to the American Dia-
betes Association (ADA), the diagnostic criteria for DM,
impaired glucose tolerance (IGT) and impaired
fasting glucose is FPG ≥ 126 mg/dL or 2-h plasma glu-
cose ≥ 200 mg/dL, 2-h plasma glucose between 140 and
199 mg/dL and a FPG between 100 and 125 mg/dL,
respectively.
Statistical analysis
Normal continuous variables were described by the mean
and standard deviation. Non-normal continuous variables
were described by the median and interquartile range (IQR).
The normality was verified by the observation of histo-
grams. Categorical variables were described by the absolute
and relative frequencies. To compare continuous variables
between two independent groups we used the Student t-test
(normal distributions) or Mann–Whitney U-test (non-nor-
mal distributions). Chi-square test (χ2) was applied to ana-
lyse independence between two categorical variables.
Univariate and multivariate logistic regression were per-
formed to study the association of each risk factor with the
caesarean. Values of p ≤ 0.05 were considered statistically
significant. Data analysis was performed using IBM
SPSS™ software version 25.
Endocrine
Results
We analysed data from 10,443 women, with a mean age of
33.2 ± 5.3 years old, of which 68.2% (n= 7123) had at least
one RF. The most common RF was first-degree relatives
with T2DM (71.8%; n= 4966/6912), followed by obesity
(45.9%; n= 3267/7123), history of GDM (21.1%; n=
1354/6404) and history of foetal macrosomia (9.2%; n=
589/6368). From 2011 to 2014, no difference in the pro-
portion of pregnant women with RF was observed. How-
ever, in 2015 there was an increase in this group compared
to previous years (75.1% vs. 66.2%; p < 0.001).
Women without RF were younger than those with RF
(32.6 years vs. 33.5 years; p < 0.001). The detailed char-
acteristics of women with GDM are described in Table 1.
The diagnosis of GDM in both groups was more fre-
quently established by OGTT at the 24–28th gestational
week than fasting glycaemia at the first pre-natal visit (60.6
vs. 39.4%; p < 0.001). Nevertheless, women with RF were
more frequently diagnosed by fasting glycaemia at the first
pre-natal visit in comparison to women without RF (40.2 vs.
37.7%; p= 0.015). The delay from diagnosis to the first
consultation with the specialized diabetes care team was
3 weeks (IQR 2.0–6.0) and was similar between groups (p
= 0.93). In the pregnant women without RF vs. with RF,
insulin therapy was less frequently initiated (38.4 vs.
48.6%; p < 0.001), the starting week of therapy was defer-
red one week (30th gestational week vs. 29th gestational
week; p < 0.001) and total daily doses of insulin were
inferior (14 insulin units vs. 18 insulin units; p < 0.001).
Moreover, treatment with metformin was less frequently
used (5.6 vs. 10.2%; p < 0.001). Regarding obstetric
complications, pre-eclampsia occurred more frequently in
women with RF (3.4 vs. 2.4%; p= 0.003), whereas no
differences in hydramnios or foetal death were observed.
Caesarean section was more commonly performed in
women with RF (38.4 vs. 30.6%; p < 0.001), although
vaginal instrumented deliveries were more frequent in
women without RF (18.2 vs. 14.0%; p < 0.001). No dif-
ferences occurred in eutocic births, in urgent or pro-
grammed caesareans, nor gestational age. The detailed
characteristics of the obstetric outcomes are described in
Table 2.
The pregnant women with first degree relatives with
T2DM, previous foetal macrosomia and a BMI > 30 kg/m2
presented an increased risk for caesarean section compared
to pregnant women without these risk factors (p < 0.001).
When adjusting these variables to each other the chance of
caesarean section remained elevated (p < 0.001). The uni-
variate and multivariate logistic regression are shown in
Tables 3 and 4.
The prevalence of LGA newborns was higher in the
group of pregnant women with RF (5.1 vs. 2.3%; p <
0.001), while pregnant women without RF gave birth more
frequently to SGA newborns (14.6 vs. 12.3%; p < 0.001).
The neonatal morbidity was higher in the newborns of
pregnant women with RF (19.3 vs. 17.5%; p= 0.040). No
differences in neonatal deaths were observed. Neonatal
outcomes are described in Table 5.
The DM reclassification test showed an increased fre-
quency of impaired fasting glycaemia, impaired glucose
tolerance and diabetes in women with RF (8.6% vs. 5.2%;
p < 0.001).
Table 1 General characteristics
of the total cohort and of
pregnant women with and
without RF
Without RF With RF Total cohort p-value
Age, years mean (±SD) 32.6 (5.4) 33.5 (5.2) 33.2 (5.3) 0.001a
Non-portuguese 14.2 11 12 0.001b
% (n/N) (361/2547) (615/5569) (976/8116)
Pregravid BMI (kg/m2) 23.7 28.3 26 0.001c
Median (IQR) (21.7–26.3) (24–33.1) (22.9-30.9)
1st degree relatives with T2DM (%) 0 71.8 48.5 0.001b
(n/N) 0/3320 (4966/6912) (4966/10232)
Previous foetal macrosomia 0 9.2 6.1 0.001b
% (n/N) 0/3320 (589/6368) (589/9688)
Previous GDM 0 21.1 13.9 0.001b
% (n/N) 0/3320 (1354/6404) (1354/9724)
Parity, n 0 1 1 0.001c
Median (IQR) (0–1) (0–1) (0–1)







Universal screening vs. risk-factor based
The IADPSG criteria used in Portugal for GDM screening
is currently recommended by the International Federation
of Gynaecology and Obstetrics and most international
organizations, with some exceptions namely the American
College of Obstetricians and Gynaecologists and NICE.
One of the limitations of risk-factor-based screening is the
difficulty to ascertain the adequate RF for each popula-
tion. Interestingly, in our study, the frequency of pregnant
women with at least one RF (68.2%) was higher in
comparison to other studies [13]. However, if risk-based-
factor screening ought to be implemented in Portugal
almost a third of pregnant women would have remained
undiagnosed. Another limitation of risk-factor-based
screening is the fact that previous history of GDM and
macrosomia are considered as risk factors, so primiparous
that may develop GDM complications during the first
pregnancy are excluded. Additionally, age, which is
known to be a traditional RF for GDM, is omitted in NICE
Table 2 Obstetric outcomes of
the total cohort and of pregnant
women with and without RF
Without RF With RF Total cohort p-value
Gestational hypertension 7.2 12.7 10.9 0.001a
% (n/N) (226/3157) (841/6626) (1067/9783)
Hydramnios 2.8 3.2 3.1 0.126a
% (n/N) (88/3711) (213/6616) (301/9793)
Pre-eclampsia 2.4 3.4 3 0.003a
% (n/N) (74/3142) (223/6613) (297/9755)
Weight gain, kg (mean ± SD) 10.9 (5.4) 9.1 (6.2) 9.7 (6) 0.001b
Therapy with insulin % (n) 38 (1256) 49 (3441) 45.4 (4697) 0.001a
Foetal death 0.3 0.4 0.3 0.285a
% (n/N) (8/3092) (24/6772) (32/9864)
Gestational age, weeks median (IQR) 39 (38-39) 39 (38-39) 39 (38-39) 0.101c
Induced delivery 35.5 40.2 38.9 0.001a
% (n/N) (319/899) (941/2343) (1260/3242)
Caesarean
% (n/N) 47.2 46.9 47
Urgent (427/905) (1133/2417) (1560/3322) 0.453a
Elective 52.8 53.1 53
(478/905) (1284/2417) (1762/3322)
Type of delivery % (n)
Eutocic 51.3 (1632) 47.6 (3223) 48.8 (4855) 0.078a
Vaginal instrumented delivery 18.2 (578) 14 (946) 15.3 (1524) 0.001a
Caesarian 30.6 (973) 38.4 (2602) 35.9 (3575) 0.001a
SD standard deviation, IQR interquartil range
aChi-square test; Mann–Whitney test
bt-test
Table 3 Univariate logistic regression
Variables OR (95% CI) p-value
1st degree relatives with T2DM
No Reference –
Yes 1.248 (1.149 – 1.356) <0.001
Previous pregnancy with GDM
No Reference –
Yes 1.099 (0.973 – 1.242) 0.130
Previous foetal macrosomia
No Reference –
Yes 1.665 (1.403 – 1.977) <0.001
BMI 1.036 (1.029 – 1.043) <0.001
Dependent variable: caesarean
T2DM type 2 diabetes mellitus, GDM gestational diabetes mellitus,
BMI body mass index
Table 4 Multivariate logistic regression
Variables: OR (95% CI) p-value
1st degree relatives with T2DM
No Reference –
Yes 1.203 (1.101 – 1.314) <0.001
Previous foetal macrosomia
No Reference –
Yes 1.468 (1.223 – 1.761) <0.001
BMI 1.035 (1.027 – 1.043) <0.001
Dependent variable: caesarean
T2DM type 2 diabetes mellitus, GDM gestational diabetes mellitus,
BMI body mass index
Endocrine
screening criteria [14]. Risk-factor-based screening is also
more complex than universal screening and requires more
attention to previous obstetric history by health profes-
sionals, which may result in inadequate screening. The
main goal of risk-factor-based screening is to recognise
pregnant women at greater risk of complications who
would most gain from intensive management, while other
pregnant women would be relieved from the burden of
further medical interventions. A more rational use of
resources would allow, for instance, a reduction of time
from diagnosis to the first consultation that in our study
was three weeks. Considering that the diagnosis of GDM
is mainly established after the 24th week, a 3-week gap
until observation and management by the specialized
diabetes care team is relevant.
Diagnosis and treatment
The increased frequency of GDM diagnosis by fasting
plasma glycaemia and the increased incidence of pre-
diabetes and DM at the reclassification test suggest that
women with RF suffer a more severe form of abnormal
glucose metabolism. However, we emphasise that the
diagnosis by fasting plasma glycaemia is not consensual
and is not recommended by ADA [15]. Our results showed
that women without RF required less frequently therapy
with insulin and in a lower dosage. Yet, still, 38% had
inadequate metabolic control and initiated insulin therapy.
In 2016, a new consensus for GDM treatment was intro-
duced in Portugal and the glycaemic targets were modified
to 95 mg/dL when fasting and 140 mg/dL one hour after the
meal, instead of 90 and 120 mg/dL in use at the time of this
study. Therefore, the proportion of women with GDM in
need of pharmacotherapy is expected to decrease.
Obstetric/Neonatal outcomes
The label of “GDM” may prompt higher rates of caesarean
section rather than clinical indication [16–18]. On the other
hand, Farrar et al. showed that after the transition from risk-
factor-based to universal screening and subsequently higher
GDM detection rates, caesarean section rates did not rise in
their population. However, there was an increase in labour
induction [8]. The prevalence of LGA in our cohort was
lower than in other studies [19]. One of the possible
explanations for this is the use of the Fenton curves for
neonatal assessment, that like shown by other authors may
underestimate LGA in comparison with other curves [20].
Additionally, these findings are probably related to the
adequate glycaemic control attained in both groups.
Nevertheless, there were significant differences in LGA
between the two groups, strengthening our hypothesis. Our
findings showed a high frequency of SGA in the whole
cohort and even higher in the group without RF. One of the
main goals of the management of women with GDM is to
control foetal growth, but tight glucose control may be
associated with a higher incidence of SGA and adverse
neonatal outcomes [21]. Thus, it is important to avoid over-
medicalization of GDM, which we think has been con-
sidered in the new glycaemic targets proposed for GDM
since 2016.
Reclassification test
The DM reclassification test revealed a higher prevalence of
abnormal glucose metabolism in women with RF. However,
of the women without any known RF, there were 5% that
also had an abnormal result. These women have a higher
risk of T2DM in the future, despite being young, non-obese
Table 5 Neonatal outcomes of
the total cohort and of pregnant
women with and without RF
Without RF With RF Total cohort p-value
Neonatal morbidity 17.5 19.3 18.7 0.021b
% (n/N) (525/2993) (1216/6293) (1741/9286)
Neonatal hypoglycaemia 3.2 4 3.7 0.024b
% (n/N) (93/2941) (248/6174) (341/9115)
Neonatal Hyperbilirubinemia 9.9 11.6 11 0.007b
% (n/N) (293/2966) (723/6235) (1016/9201)
Respiratory distress syndrome % (n/N) 2 (59/2960) 2.8 (176/6224) 2.6 (235/9184) 0.019b
Weight of newborn, kg Median (IQR) 3110 (2820-3380) 3180 (2870-3480) 3160 (2855-3450) 0.001c
Large for gestational age % (n/N) 2.3 (69/3061) 5.1 (335/6535) 4.2 (404/9596) 0.001b
Small for gestational age % (n/N) 14.6 (448/3061) 12.3 (803/6535) 13 (1251/9596) 0.001b
Adequate for gestational age % (n/N) 83.1 (2544/3061) 82.6 (5397/6535) 82.2 (7941/9596) 0.065b
Admission to intensive care unit % (n/N) 5 (149/2972) 6 (375/6239) 5.7 (524/9211) 0.054b
Congenital anomalies % (n/N) 2.2 (62/2832) 3.4 (204/6040) 3 (266/8872) 0.001b
Neonatal death % (n/N) 0.4 (8/2037) 0.2 (11/4709) 0.3 (19/6746) 0.187b





and with no family history of DM. This is a further concern
about selective screening in GDM, as these women would
not be identified and there would be no opportunity to
intervene longer-term to promote enhanced screening, life-
style change or early diagnosis of T2DM in the future.
Strengths/Limitations
The strengths of our study are the sample size obtained from
several hospitals in all regions in Portugal and by addres-
sing an issue with potential implications on current
measures.
The limitations are related to the retrospective nature of
the study, loss of data due to incomplete fill of the database,
and the international heterogeneity in screening and diag-
nostic criteria for GDM troubling comparisons between
studies. In addition, both groups were treated and the better
outcomes observed in the group without RF must be cau-
tiously interpreted. Ideally, comparisons should be estab-
lished between women diagnosed with GDM with no RF
and pregnant women glucose-tolerant in the Portuguese
population.
Nevertheless, according to current measures, additional
attention is required for pregnant women with GDM and
RF.
Conclusion
Pregnant women with RF diagnosed with GDM on uni-
versal screening had worse obstetric and neonatal outcomes
than those without RF.
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